Publications and Presentations

Publications and Papers

Lovastatin augments apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Gastroenterology, 2000;118:A681. Banke Agarwal, Petr Protiva, Prabhakar Swaroop, Ram Chuttani, William R Ramey, Peter R Holt
Cox-2 selective inhibitors induce apoptosis by Cox-2 dependent and Cox-2 independent mechanisms. – Gastroenterology, 2000;118:A52. Banke Agarwal, Prabhakar Swaroop, Petr Protiva, Ram Chuttani, Peter R Holt.
Lovastatin induced apoptosis correlates with increase in cytosolic Cdc42. Gastroenterology 116, G1614, 1999. Banke Agarwal, Alexander S. Feoktistov, Prabhakar Swaroop, Sanjay Bhendwal, Peter Protiva, William R Ramey, Ming Cheng, C Pothoulakis, J Thomas Lamont, Peter R Holt.
Sulindac sulfide induces apoptosis by both Cox-2 dependent and Cox-2 independent mechanisms and inhibits proliferation by a Cox-2 independent mechanism. Gastroenterology 116, G1615, 1999.
Sodium Phenylacetate inhibits proliferation and induces apoptosis in intestinal epithelial cells by mechanisms other than inhibition of isoprenylation. Gastroenterology 116, G1616, 1999. Banke Agarwal, Prabhakar Swaroop, Peter Protiva, Sanjay Bhendwal William R Ramey, Haim Shirin, Alexander S. Feoktistov, Peter R Holt. Banke Agarwal, Peter Protiva, Prabhakar Swaroop, Sanjay Bhendwal, Balasz Halmos, William R Ramey, Haim Shirin, Peter R Holt.
Inhibition of membrane localization of Rho is not sufficient to explain lovastatin induced apoptosis. Gastroenterology 116, G1764, 1999. Alexander S. Feoktistov, Banke Agarwal, Balasz Halmos, Prabhakar Swaroop, Sanjay Bhendwal, William R Ramey, Ming Cheng, C Pothoulakis, J Thomas Lamont, Peter R Holt.
Sodium Phenylacetate inhibits proliferation and induces apoptosis in intestinal epithelial cells by mechanisms other than inhibition of isoprenylation. Proceedings of the American Association of Cancer Research: 3837, p582, Vol 40, 1999. Agarwal B, Halmos B, Protiva P, Swaroop P, Bhendwal S, Shirin H, Ramey WR, Holt PR.
Inhibition of membrane localization of Rho is not sufficient to explain lovastatin induced apoptosis. Proceedings of the American Association of Cancer Research: 382, p57, Vol 40, 1999. Feoktistov AS, Agarwal B, Halmos B, Swaroop P, Chen M, Pothoulakis H, Lamont TJ, Holt PR.
Inhibition of membrane localization of Rho is not sufficient to explain lovastatin induced apoptosis. Gastroenterology 1999;116:G1764. Feoktistov AS, Agarwal B, Halmos B, Swaroop P, Bhendwal S, Ramey WR, Cheng M, Pothoulakis C, Lamont JT, Holt PR.
Sodium Phenylacetate inhibits proliferation and induces apoptosis in intestinal epithelial cells by mechanisms other than inhibition of isoprenylation. Gastroenterology 1999;116:G1616. Agarwal B, Protiva P, Swaroop P, Bhendwal S, Halmos B, Ramey WR, Shirin S, Holt PR.
Sulindac sulfide induces apoptosis by both Cox-2 dependent and Cox-2 independent mechanisms and inhibits proliferation by a Cox-2 independent mechanism. Gastroenterology 1999;116:G1615. Agarwal B, Swaroop P, Protiva P, Bhendwal S. Ramey WR, Shirin J, Feoktistov AS, Holt PR.
Lovastatin induced apoptosis correlates with increase in cytosolic Cdc42. Gastroenterology 1999;116:G1614. Agarwal B, Feoktistov AS, Swaroop P, Bhendwal S, Protiva P, Ramey WR, Cheng M, Pothoulakis C, Lamont JT, Holt PR.
Lovastatin augments apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Gastroenterology, 2000;118:A681. Agarwal B, Protiva P, Swaroop P, Chuttani R, Ramey WR, Holt PR.
Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis. 2003;8:649-654. Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR.
Significance of diminutive colonic polyps. Gastrointestinal Endoscopy 2005;62:AB246. Gogia S, Swaroop P, Agarwal B.
The risk of CRC and dysplasia in patients who have PSC-IBD who are on UDCA seems to be reduced with the use of mesalamine and folate. Smith T, Swaroop P Gastroenterology, 2006:139; A 1185
Portal hypertensive gastropathy is a risk factor for developing gastric polyps. Naishadh Raghuwanshi, MD, Samer El-Dirani, MD, Prabhakar P. Swaroop, MD., Am J Gastroenterol. 2006;101:S 457-458. P148
Indications for proctocolectomy and surgical outcomes in patients with inflammatory bowel disease and primary sclerosing cholangitis Smith T, Swaroop P.. Am J Gastroenterol. 2006;101:S 457-458. P1174
Endoscopic features of inflammatory bowel disease in patients with primary sclerosing cholangitis. Smith T, Swaroop P. Am J Gastroenterol. 2006;101:S454. P1164
Presence of Ileitis is a risk factor for dysplasia in patients with ulcerative colitis as well as in patients with Primary Sclerosing Cholangitis with Ulcerative Colitis. Murali N, Raghuwanshi N, Swaroop P. Gastroenterology 2007: 132. W 1105
Inflammatory Bowel Disease in the elderly. Prabhakar P. Swaroop. Clinics in Geriatric Medicine. Volume 23, Issue 4, November 2007. Pages 809-821.
Inflammatory Bowel Disease. Prabhakar P. Swaroop, Daniel K. Podolsky. Conn’s Current Therapy 2010.
Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Joo M, Abreu-e-Lima P, Farraye F, Smith T, Swaroop P, Gardner L, Lauwers GY, Odze RD. Am J Surg Pathol. 2009 Jun;33(6):854-62
CT Enterography Findings Correlate with Components of Harvey-Bradshaw Index. Tojo Thomas, Rebecca D. Chason, Rafia Bhore, Cecelia Brewington, Vasantha Vasan, Prabhakar P. Swaroop. DDW 2010. New Orleans. M 1237
Changing rates of surgical interventions, colorectal cancers, neurological disorders and emergent admissions in patients with Inflammatory Bowel Disease. Prabhakar P. Swaroop, Tojo Thomas, Craig Olson, Farshid Araghizadeh, Edward H. Livingston DDW 2010, New Orleans S 1218
Changing rates of surgical interventions, colorectal cancers and neurological disorders in patients with Inflammatory Bowel Disease. Prabhakar P. Swaroop, Tojo Thomas, Craig Olson, Farshid Araghizadeh, Edward H. Livingston Oral Presentation. OP 057. UEGW 2010, Barcelona, Spain
CT enterography findings correlate with components of Harvey Bradshaw Index. Tojo Thomas, Rebecca D. Chason, Rafia Bhore, Cecelia Brewington, Vasantha Vasan, Prabhakar P. Swaroop. Poster Presentation, P1493. UEGW 2010, Barcelona, Spain
Correlation of CT enterography findings to hsCRP, Platelets, hematocrit and BMI. Tojo Thomas, Rebecca D. Chason, Rafia Bhore, Cecelia Brewington, Vasantha Vasan, Prabhakar P. Swaroop. Poster Presentation, P 1492, UEGW 2010, Barcelona, Spain
Do CT Enterography Findings Correlate with Clinical Scores of Crohn’s disease. Prabhakar Swaroop, Tojo Thomas, Cecelia Brewington, Rafia Bhore, Vasantha Vasan. The American Journal of Gastroenterology, Volume 106, Supplement 2, October 2011. S 471, 1245. Correlation of Fecal Calprotectin to the Expression of Serum C-reactive protein. Rushikesh Shah, Henry Herrera, Candice Jantz, Rosemarie Dewald, Prabhakar Swaroop. The American Journal of Gastroenterology, Volume 106, Supplement 2, October 2011. S 479, 1259.
Does the use of EMR-based Communication between Physician and Patient Reduce the Need for Frequent Clinic visits? Rushikesh Shah, Henry Herrera, Candice Jantz, Rosemarie Dewald, Prabhakar Swaroop. The American Journal of Gastroenterology, Volume 106, Supplement 2, October 2011. S 491, 1291.
Characteristics of Anemia in IBD patients Based on Duration of Disease and Level of Inflammatory Markers. Rushikesh Shah, Henry Herrera, Candice Jantz, Rosemarie Dewald, Prabhakar Swaroop. The American Journal of Gastroenterology, Volume 106, Supplement 2, October 2011. S 494, 1298.
Predictors of elevated fecal Calprotectin in Inflammatory Bowel Disease patients Rushikesh Shah, Henry Herrera, Rosemarie Dewald, Prabhakar Swaroop, Inflammatory Bowel Disease, Volume 17, Number S2, P-85, December 2011
Can fecal Calprotectin anticipate the future clinical activity in patients with quiescent Inflammatory Bowel Disease ? Rushikesh Shah, Henry Herrera, Rosemarie Dewald, Prabhakar Swaroop Inflammatory Bowel Disease, Volume 17, Number S2, P-87 December 2011
Does Sequence of Biologic Agent Affect Longevity of Efficacy in IBD Patients: Sa 1244 Rushikesh Shah, Henry Herrera, Prabhakar Swaroop. Digestive Disease Week, San Diego, May 2012
Human Probiotic Infusion (HPI) in Ulcerative Colitis-Patient’s Perceptions and Predictors of Efficacy. Sa 1245. Rushikesh Shah, Henry Herrera, Prabhakar Swaroop .Digestive Disease Week, San Diego, May 2012
Colorectal Complication in Post-Lung Transplant Cystic Fibrosis Patients. Rushikesh Shah, Henry Herrera, Vaidehi Kaza, Prabhakar Swaroop. Tu 1177. Digestive Disease Week, San Diego, May 2012
Use of Biologics is not associated with Lower Prevalence of Extraintestinal Manifestations ( EIMs) in IBD. Radhika Ayyagiri, Sarah Khan, Rushikesh Shah, Henry Herrera, Prabhakar P. Swaroop. P1530. ACG, Las Vegas, October 2012
Infliximab in Treatment of IBD-Longevity Based upon type of Disease Sarah Khan, Radhika Ayyagiri, Rushikesh Shah, Henry Herrera, Prabhakar P. Swaroop. P1529. ACG, Las Vegas, October 2012
Biologics do not reduce the Long term risk of surgery in Patients with IBD. Sarah Khan, Radhika Ayyagiri, Henry Herrera, Rushikesh Shah, Prabhakar P. Swaroop. P1528. ACG, Las Vegas, October 2012
The Use of Oral Complementary and Alternative Medicine in Patients with Inflammatory Bowel Disease. Sarah Khan, Radhika Ayyagiri, Rushikesh Shah, Henry Herrera, Prabhakar P. Swaroop. P1527. ACG, Las Vegas, October 2012
Obesity is Linked to Higher rates of arthritis and Failure of Biologics in IBD patients. Sarah Khan, Radhika Ayyagiri, Rushikesh Shah, Henry Herrera, Prabhakar P. Swaroop. P1526. ACG, Las Vegas, October 2012
Ursodeoxycholic acid reduces the Rate of Colon polyps in patients with CF who have had lung transplantation but may increase mortality. Radhika Ayyagiri, Sarah Khan, Rushikesh Shah, Henry Herrera, Vaidehi Kaza, Prabhakar P. Swaroop. P542. ACG, Las Vegas, October 2012
Diagnostic yield of Endoscopic Procedures in patients with Chronic abdominal pain. Radhika Ayyagiri, Sarah Khan, Prabhakar P. Swaroop. P492. ACG, Las Vegas, October 2012
SSRIs, Aortic and Mesenteric Calcifications increase the risk of GI bleeding in patients with LVAD irrespective of Anticoagulation and Type of Implant. Radhika Ayyagiri, Sarah Khan, Henry Herrera, Rushikesh Shah, Jeffrey Hodges, Prabhakar P. Swaroop. Dan Meyer P360. ACG, Las Vegas, October 2012
Early failure of Infliximab in Ulcerative Colitis as compared to patients with Crohn’s disease. Rushikesh Shah, Henry Herrera, Prabhakar Swaroop. P 417. ACG, San Diego, October 2013
Development of Post–Lung Transplant Gastroesophageal Reflux Disease (GERD) in Diabetic Patients. Rushikesh Shah, Henry Herrera, Vaidehi Kaza. Prabhakar Swaroop. P 666. ACG, San Diego, October 2013
Surgical Outcomes in Colorectal Cancer Patients – Colorectal Vs Non-Colorectal Surgeons. P 1582. Rushikesh Shah, Henry Herrera, Prabhakar Swaroop. P 1582. ACG, San Diego, October 2013.

Investigator Initiated Studies:

Behavior of Hepatitis C Clinical P.I in prison population, its correlates and factors affecting response rates. Role: P.I
Safety of US guided liver biopsy Clinical P.I. over traditional liver biopsy. Role: P.I
Detection of NKT cells by using Laboratory/Human Co-Investigator Cd1d-Alfa Gal-Cer tetramers and its significance in IBD.Role: P.I
Prevention of experimental pancreatitis Laboratory/Animal P.I. in murine model by rosiglitazone, a PPAR gamma agonist. Role: P.I
Comparison of open access colonoscopy and colonoscopy scheduled through the offices of gastroenterologists.Role: P.I
A retrospective analysis of colorectal cancer and cholangiocarcinoma in patients with PSC and UC. Role: P.I
Portal hypertensive gastropathy is a risk factor for developing gastric polyps. Role: P.I
PSC and IBD patients are a different subtype of patients as compared to patients with only IBD. Role: P.I
The risk of CRC and dysplasia in patients who have PSC-IBD on UDCA. Role: P.I
Risk of surgery in patients with PSC-IBD. Clinical P.I.
Sexual Dysfunction in IBD. Clinical PI
Human Probiotic therapy. Clinical PI

Multicentric Clinical Studies

1CDP -870-032: A Phase III multinational, multicenter, double blinded, placebo controlled parallel group, 26 week study to assess the maintenance of clinical response to humanized anti-TNF PEG conjugate, in patients with active Crohn’s disease.
1CDP -870-032: A Phase III multinational, multicenter, open labeled, 52 week study to assess the safety of chronic therapy with the humanized anti-TNF PEG conjugate, CDP 870 400 mg sc, ( dosed 4 weekly from Week 48), in the treatment of patients with active Crohn’s disease who have previously completed studies CDP 870-031 or CDP 870-032 Celltech R&D Limited Protocol CDP-870-033. Role: P.I.
1CDP -870-032: A Phase III multinational, multicenter, open labeled, 52 week study to assess the safety of re-exposure after variable interval and subsequent chronic therapy with the humanized anti-TNF PEG conjugate in the treatment of patients with active Crohn’s disease who have previously been withdrawn from studies CDP 870-031 or CDP 870-032 due to an exacerbation of Crohn’s disease. Role: P.I.
Protocol C0379T07: A multicenter, randomized Phase 2a study of human monoclonal antibody to IL-12p40 (CNTO 1275) in subjects with moderately to severely active Crohn’s disease. Role: P.I.
A randomized, double-blind, placebo-controlled, parallel group, multi-center study to investigate the safety and efficacy of CP-690,550 in subjects with moderate to severe Crohn’s Disease. Role : P.I.

Invited Lectures and Presentations

Clostridium Difficile Infection in Hospitalized Patients. Gastroenterology conference; Lemuel Shattuck Hospital. Jan 2002.
Acute Hepatitis C, and recent advances: Hepatology Conference. Brigham and Women’s Hospital. Harvard University. Jan 2002.
A Case of esophageal Cancer and latest advances in esophageal stenting. Combined GI-Surgical Conference. Faulkner Hospital. August 2001.
Diarrhea in the AIDS patient with special emphasis on Microsporidia. Gastroenterology Conference. Lemuel Shattuck Hospital. Jan 2002.
A Case of Gastric Cancer: Combined Longwood Academic Conference. September 2000.
A Case of Retroperitoneal Fibrosis in association with Pheochromocytoma. Inter City GI conference organized by the Brigham and Women’s Hospital, September 2000.
Role of IL-10 and hepatic fibrosis. Fellow’s Conference, Brigham and Women’s Hospital GI Conference. February 2001
Sulindac sulfide induces apoptosis by both Cox-2 dependent and Cox-2 independent mechanisms and inhibits proliferation by a Cox-2 independent mechanism. Presented in the Gastrointestinal Research Conference at the Faulkner Hospital. July 2000.
Inferior Vein Thrombosis associated with Acute Pancreatitis. An unusual vascular complication-It’s presentation and management. Longwood GI conference. Brigham and Women’s Hospital. October 2000.

Malignant Ascites: Longwood GI conference: May 2001
Crohn’s disease and Infliximab: Longwood GI conference: May 2001
Acute Liver failure: definitions and management; GI conference of the Faulkner hospital. October 2001

Fever of Unknown origin. Longwood GI conference. December 2001

Invited lectureships – National and International

Invited speaker. Common medical problems around the world. June 28-July 3, 2004. Bangkok, Thailand. Sponsored by SLU and Thai-American Physicians.
Invited speaker. Infectious diseases of the GI tract. June 28-July 3, 2004. Bangkok, Thailand. Sponsored by SLU and Thai-American Physicians.
Invited speaker. Inflammatory Bowel Disease. June 28-July 3, 2004. Bangkok, Thailand. Sponsored by SLU and Thai-American Physicians.
Invited speaker. Hepatitis C: Diagnosis and Management: June 28-July 3, 2004. Bangkok, Thailand. Sponsored by SLU and Thai-American Physicians.
Invited speaker. Diarrheal diseases. June 28-July 3, 2004. Bangkok, Thailand. Sponsored by SLU and Thai-American Physicians.
Invited speaker. How close are we in curing IBD? Grand Round, St. Mary’s Hospital , St. Louis, MO. 2004.
Invited speaker. Diagnosis and management of Irritable Bowel Syndrome. Pharmacists Association of Illinois, Springfield, IL. 2004.
Invited speaker. Update on IBD/Crohn’s Disease. September 30, 2004. 2nd Annual Update in Gastroenterology. Mercy Regional Health Center, Manhattan, KS 66505.
Invited speaker. Management of CC (Chronic constipation) and IBS-C. St. Louis University Family Practice Program. Belleville. IL May 2006.
Invited speaker. IBD: Update in diagnosis and Management. Internal Medicine, Grand Rounds, Methodist Hospital, Dallas, TX January 2009.
Invited Speaker: Advances in IBD. Trinity Mother Frances Hospital, Tyler, Texas, September 2009.
Invited Speaker: Update in treatment of IBD . September 2010, Hendricks Hospital, Abilene, Texas
Invited Speaker. IBD. 2010. Trinity Mother Frances Hospital, Tyler, Texas, September 2010.
Invited Speaker. IBD. 2011. Trinity Mother Frances Hospital, Tyler, Texas, September 2011.
Invited Speaker. Advances in diagnosis and Management of IBD. 1st Annual GI symposium. Amarillo Endoscopy Center, March 2012 Amarillo, Texas
Invited Speaker. Inflammatory Bowel Disease: Advances in Diagnosis and Treatment Options. May 2012. 7th Annual TIPS ( Texas Indo American Physicians Society) CME – Update in Medicine, Dallas, Texas
Invited Speaker. Case reports in IBD. Advances in Gastroenterology and Hepatology CME annual conference Trinity Mother Frances Hospital, Tyler, Texas, September 2012
Invited Speaker: Integrating Guidelines to your Clinical Practice. TSGE ( Texas Society of Gastroenterology and Hepatology Annual CME Conference. Dallas, September 2012.
Advances in the diagnosis and treatment of IBD: Grand Rounds: Forest Park Hospital, St. Louis, MO. 2004.
Clinical efficacy and safety of Zelnorm: SIU Medical School. Grand Rounds. 2004.
Genetic Discoveries in IBD: Gastroenterology Grand Round, St. Louis University, St. Louis, MO. 2004.
Long term safety of oral budesonide: Journal Club, Division of GI, St. Louis University, St. Louis, MO. 2004.
Measures of disease activity in IBD: Gastroenterology Grand Rounds, St. Louis University, St. Louis, MO. 2004.
Lower GI bleeding: Noon Conference, St. Louis University, St. Louis, MO. 2004
Common controversies in IBD: Noon Conference, St, Louis University, St. Louis, MO. 2004.
Interaction of 6-MP and Azathioprine with 5-ASA compounds: Journal Club, Division of GI, St. Louis University, St. Louis, MO. 2004.
Diagnosis and Management of Inflammatory Bowel Disease. Lecture for PA Students. Saint Louis University. May 2006.
Microbiology of the Gut: Grand Rounds. St. Louis University Hospital, August 2006.
Review of Biologic Agents: Gastroenterology Grand Rounds, St, Louis University Hospital. Jan 2007.
IBD emergencies: September 2007. UTSW Fellows conference.
IBD: Diagnosis and Management. Grand Rounds, Internal Medicine. UTSW Medical Center, Dallas, TX. July 2009
Diagnosis and Management of IBD: MS 3 lecture, UT Southwestern Medical Center, August 2009,
IBD: What’s new? Lecture for PA students. UTSW Medical Center. September 2009
Diagnosis and Management of IBD: MS 3 lecture, UT Southwestern Medical Center, February 2010